The company appears in FDA device records as an applicant and manufacturing establishment for posterior chamber intraocular lenses used in cataract surgery. Its documented U.S. activity centers on one premarket approval, P100016, and supplements to it, rather than on a broad device catalog. The FDA record lists the applicant at 1040 S. Vintage Ave., Bldg. A, Ontario, California, which is a filing address in those records and not evidence of a corporate headquarters. ZEISS product documentation separately describes the CT LUCIA 202 and CT LUCIA 602 as sterile, foldable, hydrophobic acrylic, monofocal, posterior chamber three-piece intraocular lenses. [1][2][5]
The P100016 approval and its scope
FDA records show P100016 approved on 2010-10-19 for the EC-3 Intraocular Lens and EC-3 Precision Aspheric Lens (PAL) IOL, with Carl Zeiss Meditec Production, LLC as applicant. The approval statement describes the device as indicated for primary implantation in the capsular bag of the eye for visual correction of aphakia in adult patients whose cataractous lens has been removed. The record classifies the device as Class III, regulation number 886.3600, product code HQL, under the Ophthalmic advisory committee. [2]
The same approval record carries a Federal Register notice date of 2010-11-17 and docket number 10M-0556. The submission was received 2010-04-22 and was not flagged for expedited review. These details describe the original approval only; they do not establish later labeling, availability or performance. [2]
A 2026 manufacturing supplement
Supplement S028 to P100016 was received 2026-09-28 and decided 2026-10-23 under decision code OK30, a 30-day notice. The supplement reason is listed as a process change affecting manufacturer, sterilizer, packager or supplier. The action description covers changes to the tray raw material and lid coating for the CT LUCIA 621P intraocular lens and a sterilization process change removing the ambient aeration step from ethylene oxide sterilization for the CT LUCIA 202, CT LUCIA 602 and CT LUCIA 621P lenses. [1]
The supplement record names the trade name as CT LUCIA Intraocular Lenses (IOLs) and lists the same Ontario, California address as the applicant location. It does not report clinical data, and the 30-day notice decision should not be read as a finding on lens performance. [1]
Product family as described by the manufacturer
ZEISS instructions for use for CT LUCIA 202 and CT LUCIA 602 describe both as sterile, foldable, hydrophobic acrylic, monofocal, posterior chamber three-piece intraocular lenses. In that document, CT LUCIA 202 is listed as spherical and UV-blocking, while CT LUCIA 602 is listed as aspheric, correcting spherical aberrations and blocking UV light. The document was last revised 2026-04-16 and is published by Carl Zeiss Meditec AG of Jena, Germany. [5]
A ZEISS product page describes CT LUCIA 621P as using ZEISS Optic features intended to reduce spherical aberration while addressing potential decentration and lens misalignment, with a reinforced optic-haptic junction and a step-vaulted C-loop. That page states the product is available for US customers only. These are manufacturer descriptions, not independently verified clinical results. [6]
An FDA device listing record for product code HQL lists proprietary names CT LUCIA 202, CT LUCIA 602, CT LUCIA 611P and CT LUCIA 621P under the classification name Intraocular Lens. A separate FDA establishment record lists Carl Zeiss Meditec Production, LLC at the Ontario address with registration number 3010126268 and status Active, dated 2026. [3][8]
How to read the filing record
The linked collection contains two premarket approval records as of the snapshot date: one original approval and one 30-day notice, with decision counts of one APPR and one OK30. The smaller record sample likewise contains one of each. These counts describe the retrieved filings only and are not measures of total portfolio size, sales or safety performance. [1][2]
The applicant name on the FDA filings is Carl Zeiss Meditec Production, LLC. ZEISS technical documentation identifies Carl Zeiss Meditec Production, LLC at the Ontario address alongside Carl Zeiss Meditec USA, Inc. of Dublin, California, and Carl Zeiss Meditec AG of Jena as publishers of separate materials. The records reviewed do not establish a parent-subsidiary relationship, ownership structure or corporate headquarters, and none should be inferred from shared branding or addresses. [4][5]
